CYPHERPUNK TECHNOLOGIES INC.
Close on Oct 19, 2026
- Market cap
- $549.88M
- P/E (TTM)
- 36.1
- Dividend yield
- –
About Cypherpunk Technologies
Pharmaceutical Preparations, SIC 2834
Cypherpunk Technologies Inc. is a privacy technology company focused on advancing privacy-preserving infrastructure for the digital economy and developing novel therapies for cancer patients. The company operates two primary segments: its privacy technology business and its biotechnology subsidiary, Leap Therapeutics, Inc. Within its privacy division, the company identifies, develops, and invests in privacy-enhancing technologies, anchored by a digital asset treasury strategy focused on the Zcash network and its native cryptocurrency, ZEC. Through Leap Therapeutics, it researches and develops biomarker-targeted antibody therapies, primarily sirexatamab for colorectal and other cancers, as well as a preclinical antibody program, FL-501, for cachexia. The company serves oncology patients through its therapeutic pipeline while targeting users and participants within the decentralized digital economy.
The company conducts its biotechnology operations through wholly owned subsidiaries in the United States and Australia, including HealthCare Pharmaceuticals Pty Ltd. Cypherpunk Technologies Inc. is incorporated in the state of Delaware, with its primary corporate identity rooted in the United States.
Summary of the business section of Cypherpunk Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CYPHERPUNK TECHNOLOGIES INC.
- Founded
- 2011
- Headquarters
- Cambridge, MA
- Address
- 47 Thorndike Street, Suite B1-1 02142
- Phone
- (617) 252-4343
- Website
- cypherpunk.com
- Employees
- 6, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- EisnerAmper LLP, Philadelphia, Pennsylvania
Stock & identifiers
- Ticker
- CYPH
- Exchange
- Nasdaq
- IPO date
- Jan 25, 2017
- Shares outstanding
- 108M, Aug 10, 2026
- Public float
- $12.10M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-10 reverse, Jun 21, 2023; 1-for-10 reverse, Jun 21, 2023
- SEC CIK
- 1509745
- CUSIP
- 52187K200
- ISIN
- US52187K2006
- LEI
- 549300T31SMMJ2DDLI13
- EIN
- 27-4412575
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| William Patrick McEvoy III | Chief Investment Officer, Director | 24,854,613 |
| Douglas E. Onsi | CEO,CFO,Pres.,GC,Treas.&Sec., Director | 106,858 |
| Kevin Zhang | Head of Mining | 330,904 |
| John Mark O'Mahony | Chief Manufacturing Officer | 27,500 |
| Augustine Lawlor | Chief Operating Officer | 706,042 |
| Jason Baum | Chief Scientific Officer | 15,896 |
| Christine Granfield | VP, Head of Reg Affairs/Qual | 22,500 |
| Cynthia Sirard | Chief Medical Officer | 27,500 |
| Patricia A. Martin | Director | 118,750 |
| Khing Djien Oei | Director | 0 |
| Amanda Fabiano | Director | – |
| Thomas John Dietz | Director | 132,500 |
| Nissim Mashiach | Director | 168,750 |
| William Li | Director | 74,700 |
| Christian M. Richard | Director | 74,700 |
| Christopher Mirabelli | Director | 130,376 |
| Richard Schilsky | Director | 74,700 |
| James H. Cavanaugh | Director | 168,963 |
| Joseph Loscalzo | Director | 168,750 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Douglas Onsi | $4.75M | $5.50M | $3.76M | $26 | – |
| FY2024 Douglas Onsi | $1.48M | $1.22M | $1.04M | $64 | – |
| FY2023 Douglas Onsi | $1.53M | $1.67M | $1.00M | $92 | – |
| FY2022 Douglas Onsi | $1.88M | -$1.62M | $1.36M | $14 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 6 full-time employees.”
Corporate history
Events identified from SEC filings